Li Jiawei, Feng Lili, Lu Yingmei
Department of Physiology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
The First Clinical Medical College of Nanjing Medical University, Nanjing, Jiangsu 211166, China.
J Biomed Res. 2022 Oct 28;37(1):47-58. doi: 10.7555/JBR.36.20220156.
Glioblastoma multiforme (GBM) is an essentially incurable brain tumor, which has been explored for approximately a century. Nowadays, surgical resection, chemotherapy, and radiation therapy are still the standardized therapeutic options. However, due to the intrinsic invasion and metastasis features and the resistance to chemotherapy, the survival rate of glioblastoma patients remains unsatisfactory. To improve the current situation, much more research is needed to provide comprehensive knowledge of GBM. In this review, we summarize the latest updates on GBM treatment and invasion. Firstly, we review the traditional and emerging therapies that have been used for GBM treatment. Given the limited efficiency of these therapies, we further discuss the role of invasion in GBM recurrence and progression, and present current research progress on the mode and mechanisms of GBM invasion.
多形性胶质母细胞瘤(GBM)是一种基本上无法治愈的脑肿瘤,人们对其进行研究已有约一个世纪。如今,手术切除、化疗和放疗仍是标准化的治疗选择。然而,由于其固有的侵袭和转移特性以及对化疗的耐药性,胶质母细胞瘤患者的生存率仍然不尽人意。为改善当前状况,需要开展更多研究以全面了解GBM。在本综述中,我们总结了GBM治疗和侵袭方面的最新进展。首先,我们回顾了已用于GBM治疗的传统和新兴疗法。鉴于这些疗法的疗效有限,我们进一步讨论侵袭在GBM复发和进展中的作用,并介绍GBM侵袭模式和机制的当前研究进展。
J Biomed Res. 2022-10-28
Ann Transl Med. 2021-6
Cancers (Basel). 2023-4-1
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2023-1
Cells. 2017-11-22
Cancer Biother Radiopharm. 2019-8
Ann Clin Transl Neurol. 2025-7
Int J Mol Sci. 2025-4-18
Discov Nano. 2024-12-24
Biomol Ther (Seoul). 2025-1-1
Pharmacol Rep. 2025-2
Bioengineering (Basel). 2024-1-18
Acta Clin Croat. 2022-2
Cancers (Basel). 2021-12-24
Biomater Sci. 2022-2-15
Cancer Radiother. 2022
Food Funct. 2021-11-1
Cancer Res. 2021-10-1
Aging (Albany NY). 2021-9-29
Cell Death Dis. 2021-9-3